Siegfried-Col

active

Financing to Laboratorios Siegfried S.A.S (“Siegfried-Col”) and Laboratorios Siegfried, S.A. (jointly the “Borrowers”) to support the execution of their strategic plan including: (i) Capex needed to upgrade the manufacturing plant owned by Siegfried-Col, (ii) working capital requirements for the commercialization of Novartis’ products in light of the recent license-in agreement signed between the Borrowers’ and Novartis; and (iii) reprofile the Borrowers’ existing debt with commercial banks to properly match the long-term nature of the investments undertaken by the Borrowers over the past years and free-up the cash needed to execute their strategic plan within the next 2-3 years (the “Project”). Siegfried-Col is a leading pharmaceutical company focused on the development, manufacture and commercialization of over-the-counter medicines, prescription drugs and personal care products (mostly branded generics). With two manufacturing plants in Colombia and 516 employees, Siegfried-Col is focused mainly on cardio, neuro, women’s health and primary care therapeutic areas. Approximately 95% of Siegfried-Col’s revenues are generated in Colombia, and the rest is exported to Central America, Ecuador, and Peru.